AAO 2024 Insights
AAO 2024 Insights: Subcutaneous VRDN-003 vs. Veligrotug (VRDN-001), Full Antagonist Monoclonal Antibodies to IGF-1R for Thyroid Eye Disease - Phase 1 Safety/PK/PD Studies in Healthy Volunteers
By
AAO 2024 Insights
FEATURING
Jody Abrams
By
AAO 2024 Insights
FEATURING
Jody Abrams
Comments 0
Login to view comments.
Click here to Login
